Taysha Gene Therapies (TSHA) Stock Statistics & Valuation Metrics

Taysha Gene Therapies has a market cap or net worth of $2.06B. The enterprise value is $1.29B.

Taysha Gene Therapies has 324,861,020 shares outstanding. The number of shares has decreased by -2.65% in one year.

Taysha Gene Therapies’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -34.88%.

The current PE Ratio of Taysha Gene Therapies is ―. Taysha Gene Therapies’s PEG ratio is 2.91.

In the last 12 months, Taysha Gene Therapies had revenue of 9.77M and earned -109.00M in profits. Earnings per share was -0.34.

In the last 12 months, operating cash flow was -111.95M and capital expenditures -3.38M, giving a free cash flow of -115.33M billion.

Taysha Gene Therapies pays an annual dividend of ―, resulting in a dividend yield of ―

Taysha Gene Therapies upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).

Taysha Gene Therapies as a current ratio of 12.23, with Debt / Equity ratio of 8.38%

In the past 12 months, Taysha Gene Therapies has paid 0.00 in taxes.

Taysha Gene Therapies EV to EBITDA ratio is -11.41, with an EV/FCF ratio of -13.11.

Taysha Gene Therapies has $276.58M in cash and marketable securities with $17.77M in debt, giving a net cash position of $258.81M billion.

Gross margin is 88.22%, with operating margin of -1130.65%, and net profit margin of -1115.27%.

The average price target for Taysha Gene Therapies is $12.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy